SAN.PA
$77.79-0.36 (-0.46%)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Recent News
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028
Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, recent portfolio decisions, partnership economics, and cash runway during a fireside chat hosted by KeyBank healthcare tech equity analy
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.
Earendil Labs, an AI-powered drugmaker, hauls in $787M
The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi.
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
European equities traded in the US as American depositary receipts were down sharply late Thursday m
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.